{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:51:44Z","timestamp":1792461104176,"version":"4.5.0"},"reference-count":40,"publisher":"Cambridge University Press (CUP)","issue":"7","license":[{"start":{"date-parts":[[2014,8,20]],"date-time":"2014-08-20T00:00:00Z","timestamp":1408492800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":["journals.cambridge.org"],"crossmark-restriction":true},"short-container-title":["Epidemiol. Infect."],"published-print":{"date-parts":[[2015,5]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>The objectives of this study were to characterize methicillin-resistant<jats:italic>Staphylococcus aureus<\/jats:italic>(MRSA) blood culture isolates and to determine their relative importance in both nosocomial and community-acquired infections. A total of 535 MRSA blood culture isolates were analysed.<jats:italic>In vitro<\/jats:italic>susceptibility to 14 agents was determined. The genes<jats:italic>nuc, mecA<\/jats:italic>and coding for PVL toxin were identified by PCR. All isolates were characterized by PFGE or<jats:italic>spa<\/jats:italic>typing to assess their genomic relationships. Most MRSA isolates were retrieved from nosocomial bloodstream infections (474, 89%) and were of the CMRSA2 genotype. Healthcare-associated (HA)-MRSA bloodstream infections were associated with older age (70\u201389 years,<jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b7002) and most often secondary to central line infections (<jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b7005). Among MRSA strains associated with community-acquired (CA)-MRSA, 28\u00b78% were isolated in intravenous drug users. CA-MRSA genotypes were more frequently found in young adults (20\u201339 years,<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00\u00b70001) with skin\/soft tissue as the primary sources of infection (<jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b7006). CMRSA10 genotype was the predominant CA-MRSA strain. All MRSA isolates were susceptible to doxycycline, tigecycline, trimethoprim\/sulfamethoxazole and vancomycin. Both the presence of the genes coding for PVL toxin (89\u00b78%) and susceptibility to clindamycin (86\u00b75%) were predictive of CA-MRSA genotypes. Whereas in the USA, HA-MRSA have been replaced by USA300 (CMRSA10) clone as the predominant MRSA strain type in positive blood cultures from hospitalized patients, this phenomenon has not been observed in the province of Quebec.<\/jats:p>","DOI":"10.1017\/s095026881400209x","type":"journal-article","created":{"date-parts":[[2014,8,20]],"date-time":"2014-08-20T13:49:07Z","timestamp":1408542547000},"page":"1511-1518","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":5,"title":["Molecular epidemiology and antimicrobial susceptibility profiles of methicillin-resistant<i>Staphylococcus aureus<\/i>blood culture isolates: results of the Quebec Provincial Surveillance Programme"],"prefix":"10.1017","volume":"143","author":[{"given":"S.","family":"L\u00c9VESQUE","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"BOURGAULT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. A.","family":"GALARNEAU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"MOISAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"DOUALLA-BELL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"TREMBLAY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2014,8,20]]},"reference":[{"key":"S095026881400209X_ref10","doi-asserted-by":"publisher","DOI":"10.1086\/589717"},{"key":"S095026881400209X_ref4","doi-asserted-by":"publisher","DOI":"10.1155\/2005\/698181"},{"key":"S095026881400209X_ref7","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00081-09"},{"key":"S095026881400209X_ref29","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268810000464"},{"key":"S095026881400209X_ref14","doi-asserted-by":"publisher","DOI":"10.1086\/665323"},{"key":"S095026881400209X_ref1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.14.4.385"},{"key":"S095026881400209X_ref37","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.4.1716-1721.2005"},{"key":"S095026881400209X_ref27","doi-asserted-by":"publisher","DOI":"10.1086\/651313"},{"key":"S095026881400209X_ref18","volume-title":"E-test, antimicrobial susceptibility testing for in vitro diagnostic use","year":"2010"},{"key":"S095026881400209X_ref28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2009.02969.x"},{"key":"S095026881400209X_ref31","doi-asserted-by":"publisher","DOI":"10.3201\/eid0908.030089"},{"key":"S095026881400209X_ref17","volume-title":"Performance standards for antimicrobial disk susceptibility test; approved standard \u2013 eleventh edition, M02-A11","year":"2012"},{"key":"S095026881400209X_ref23","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.12.5442-5448.2003"},{"key":"S095026881400209X_ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2010.10.028"},{"key":"S095026881400209X_ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-012-1711-x"},{"key":"S095026881400209X_ref16","volume-title":"Performance standards for antimicrobial susceptibility testing, twenty-second informational supplement, M100-S22","year":"2012"},{"key":"S095026881400209X_ref19","unstructured":"EUCAST. Breakpoint tables for interpretation of MICs and zone diameters (version 2.0). 2012. European Society of Clinical Microbiology and Infectious Diseases."},{"key":"S095026881400209X_ref34","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05804-11"},{"key":"S095026881400209X_ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2006.07.007"},{"key":"S095026881400209X_ref13","unstructured":"Comit\u00e9 de surveillance provinciale des infections nosocomiales (SPIN-SARM). Provincial surveillance of S. aureus bloodstream infections, Report 2011\u20132012. Institut national de sant\u00e9 publique du Qu\u00e9bec, 2012."},{"key":"S095026881400209X_ref2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.10.3481-3485.2001"},{"key":"S095026881400209X_ref9","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200969060-00004"},{"key":"S095026881400209X_ref40","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1128\/AEM.22.5.812-817.1971","article-title":"Reversal of the antimicrobial activity of trimethoprim by thymidine in commercially prepared media","volume":"22","author":"Koch","year":"1971","journal-title":"Applied Microbiology"},{"key":"S095026881400209X_ref35","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01717-09"},{"key":"S095026881400209X_ref8","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt026"},{"key":"S095026881400209X_ref22","doi-asserted-by":"publisher","DOI":"10.1086\/313461"},{"key":"S095026881400209X_ref6","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.061370"},{"key":"S095026881400209X_ref21","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1128\/JCM.32.7.1768-1772.1994","article-title":"Multiplex PCR for identification of methicillin-resistant staphylococci in the clinical laboratory","volume":"32","author":"Geha","year":"1994","journal-title":"Journal of Clinical Microbiology"},{"key":"S095026881400209X_ref15","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, ninth edition, M07-A9","year":"2012"},{"key":"S095026881400209X_ref39","doi-asserted-by":"publisher","DOI":"10.1139\/W09-109"},{"key":"S095026881400209X_ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2012.04.009"},{"key":"S095026881400209X_ref5","doi-asserted-by":"publisher","DOI":"10.1155\/2006\/402361"},{"key":"S095026881400209X_ref12","doi-asserted-by":"publisher","DOI":"10.1086\/342292"},{"key":"S095026881400209X_ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bios.2013.05.031"},{"key":"S095026881400209X_ref32","unstructured":"Couillard M , Tremblay C . 2011\u20132012 activity report of the Quebec Public Health Laboratory. Institut national de sant\u00e9 publique du Qu\u00e9bec, 2013."},{"key":"S095026881400209X_ref3","doi-asserted-by":"publisher","DOI":"10.3201\/eid1106.041146"},{"key":"S095026881400209X_ref11","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.5.1323-1336.2001"},{"key":"S095026881400209X_ref26","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02311-06"},{"key":"S095026881400209X_ref38","doi-asserted-by":"publisher","DOI":"10.1086\/523763"},{"key":"S095026881400209X_ref24","doi-asserted-by":"publisher","DOI":"10.1155\/2008\/754249"}],"container-title":["Epidemiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S095026881400209X","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,23]],"date-time":"2020-08-23T14:19:37Z","timestamp":1598192377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S095026881400209X\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,20]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S095026881400209X"],"URL":"https:\/\/doi.org\/10.1017\/s095026881400209x","relation":{},"ISSN":["0950-2688","1469-4409"],"issn-type":[{"value":"0950-2688","type":"print"},{"value":"1469-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,20]]},"assertion":[{"value":"Copyright \u00a9 Cambridge University Press 2014\u00a0","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}]}}